We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA approved Shire’s amphetamine-based attention-deficit/hyperactivity disorder (ADHD) drug Vyvanse, which has a lower risk of abuse than similar drugs, the company announced.